147 related articles for article (PubMed ID: 18838440)
1. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.
Stein WD; Figg WD; Dahut W; Stein AD; Hoshen MB; Price D; Bates SE; Fojo T
Oncologist; 2008 Oct; 13(10):1046-54. PubMed ID: 18838440
[TBL] [Abstract][Full Text] [Related]
2. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
Stein WD; Gulley JL; Schlom J; Madan RA; Dahut W; Figg WD; Ning YM; Arlen PM; Price D; Bates SE; Fojo T
Clin Cancer Res; 2011 Feb; 17(4):907-17. PubMed ID: 21106727
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.
Stein WD; Yang J; Bates SE; Fojo T
Oncologist; 2008 Oct; 13(10):1055-62. PubMed ID: 18827177
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review.
Colloca G
Cancer Treat Rev; 2012 Dec; 38(8):1020-6. PubMed ID: 22503300
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?
Schröder FH; Kranse R; Barbet N; Hop WC; Kandra A; Lassus M
Prostate; 2000 Feb; 42(2):107-15. PubMed ID: 10617867
[TBL] [Abstract][Full Text] [Related]
6. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
[TBL] [Abstract][Full Text] [Related]
7. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
Scher HI; Eisenberger M; D'Amico AV; Halabi S; Small EJ; Morris M; Kattan MW; Roach M; Kantoff P; Pienta KJ; Carducci MA; Agus D; Slovin SF; Heller G; Kelly WK; Lange PH; Petrylak D; Berg W; Higano C; Wilding G; Moul JW; Partin AN; Logothetis C; Soule HR
J Clin Oncol; 2004 Feb; 22(3):537-56. PubMed ID: 14752077
[TBL] [Abstract][Full Text] [Related]
8. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
9. Clinical observations on the doubling time of prostate cancer.
Schmid HP; McNeal JE; Stamey TA
Eur Urol; 1993; 23 Suppl 2():60-3. PubMed ID: 7685704
[TBL] [Abstract][Full Text] [Related]
10. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint.
Perez CA; Michalski JM; Lockett MA
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1287-96. PubMed ID: 11286836
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
Grande M; Carlström K; Rozell BL; Stege R; Pousette A
Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
[TBL] [Abstract][Full Text] [Related]
12. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen levels as a predictor of lethal prostate cancer.
Fall K; Garmo H; Andrén O; Bill-Axelson A; Adolfsson J; Adami HO; Johansson JE; Holmberg L;
J Natl Cancer Inst; 2007 Apr; 99(7):526-32. PubMed ID: 17405997
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.
Preston DM; Bauer JJ; Connelly RR; Sawyer T; Halligan J; Leifer ES; McLeod DG; Moul JW
Urology; 1999 Jan; 53(1):131-8. PubMed ID: 9886602
[TBL] [Abstract][Full Text] [Related]
17. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
Wilkerson J; Abdallah K; Hugh-Jones C; Curt G; Rothenberg M; Simantov R; Murphy M; Morrell J; Beetsch J; Sargent DJ; Scher HI; Lebowitz P; Simon R; Stein WD; Bates SE; Fojo T
Lancet Oncol; 2017 Jan; 18(1):143-154. PubMed ID: 27979599
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
[TBL] [Abstract][Full Text] [Related]
19. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?
Zagars GK; Kavadi VS; Pollack A; von Eschenbach AC; Sands ME
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):21-32. PubMed ID: 7536722
[TBL] [Abstract][Full Text] [Related]
20. Using splines to detect changes in PSA doubling times.
Guess B; Jennrich R; Johnson H; Redheffer R; Scholz M
Prostate; 2003 Feb; 54(2):88-94. PubMed ID: 12497581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
